{
    "nct_id": "NCT03822351",
    "official_title": "A Phase 2 Open-label, Multicenter, Randomized, Multidrug Platform Study of Durvalumab (MEDI4736) Alone or in Combination With Novel Agents in Subjects With Locally Advanced, Unresectable (Stage III) Non-small Cell Lung Cancer (COAST)",
    "inclusion_criteria": "1. Written informed consent and any locally required authorization obtained from the subject prior to performing any protocol-related procedures, including screening evaluation\n2. Age 18 years or older\n3. Body weight ≥ 35 kg\n4. Subjects must have histologically or cytologically documented NSCLC who present with locally advanced, unresectable, Stage III disease\n5. Subjects must have completed, without progressing, definitive cCRT within 42 days prior to being randomized into the study\n6. Provision of tumor tissue sample, when available, from original diagnosis obtained before initiation of chemoradiotherapy\n7. Life expectancy ≥ 12 weeks\n8. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1\n9. Subjects must have at least one previously irradiated tumor lesion that can be measured by RECIST v1.1\n\nMain\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 99 Years",
    "exclusion_criteria": "1. Mixed small cell and non-small cell lung cancer histology\n2. Current or prior use of immunosuppressive medication within 14 days before the first dose of study drug\n3. Prior exposure to any anti-PD1, anti-PD-L1, or anti-CTLA4 antibody for treatment of NSCLC\n4. Subjects with history of ≥ Grade 2 pneumonitis from prior chemoradiation therapy\n5. Subjects with a history of venous thrombosis within the past 3 months\n6. Subjects with history of myocardial infarction, transient ischemic attack, or stroke in the past 6 months\n7. Congestive heart failure\n8. Active or prior documented autoimmune or inflammatory disorders\n9. History of active primary immunodeficiency\n10. Active infection including tuberculosis, hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)\n11. History of allogenic organ transplantation\n12. QTcF interval ≥ 470 ms\n13. History of another primary malignancy\n14. Concurrent enrollment in another clinical study [concurrent enrollment in an observational (non-interventional) clinical study or during the follow-up period of an interventional study is permitted]\n15. Females who are pregnant, lactating, or intend to become pregnant during their participation in the study",
    "miscellaneous_criteria": "Main"
}